

Press release 2013-01-10

WntResearch: Patents granted for Foxy-5 in China, Australia and Japan

WntResearch AB (WNT.ST) announces that the patent application for the lead compound of WntResearch, that is Foxy-5, has been granted in China, Australia and Japan.

CEO Nils Brünner comments:

"The grant of patents for WntResearch's lead compound Foxy-5 in China, Australia and Japan is very satisfactory and in line with the IP-strategy for Foxy-5. The granting is an important step towards development and commercialization. It is a pre-requisite for partner negotiations and supports that FOXY-5 as an anti-metastatic drug is a new and innovative concept."

For further information please contact:

Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: +45 2614 4708

About WntResearch AB

WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is planned to enter phase 1 clinical trials in metastatic cancer in the end of 2012 / beginning of 2013.